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Background / Study Objective
• Shear-mediated platelet activation is the major driver of thromboembolic
complications associated with LVADs.
• The possibility of detecting shear-mediated platelet activation with a
specific methodology is still not readily available for clinical use.
• The Platelet Activity State (PAS) assay may serve as a reliable tool to
quantitate shear-mediated platelet activation and correlate it with clinical
VAD-related complications.
Aim of the study: To assess platelet activation in patients with LVAD using the
PAS assay and to correlate results with thromboembolic complications
associated with LVADs.
Patients
• 10 consecutive patients implanted with LVADs were involved in the study
(5 Thoratec HMII, 5 Heartware HVAD, 76 ± 71 days after implant).
• 334 cumulative days of LVAD support.
• Patients received the following anti-thrombotic agents: Bivalirudin and
subsequently coumadin + aspirin.
• LDH, fibrinogen and plasma free hemoglobin concentrations were
measured contemporaneously with PAS determination. Physiological
range values for LDH, fibrinogen and plasma free hemoglobin
concentration in blood of healthy subjects were defined as 125-220 U/L,
150-400 mg/dl and 14-18 g/dl, respectively.
Methods
• Whole blood (20 ml) was drawn via venipuncture into 3 ml acid-citrate
dextrose (ACD-A) from consenting LVAD patients.
• Blood was centrifuged at 500g for 15 min to obtain platelet-rich plasma (PRP).
• PRP was gel-filtered through a column of Sepharose 2B beads to collect gel-
filtered platelets (GFP).
• GFP were diluted to a count of 20,000 platelet/µl.
• Platelet activation level was assessed via PAS assay (spectrophotometric
analysis over 8 min, λ = 405 nM).
• Linear regression analysis was performed on the changes in absorbance/min.
The values obtained were normalized against the thrombin generation rate of
fully activated platelets, obtained by sonication (10 W for 10 s).
• All PAS values were expressed as a percentage of the maximum thrombin-
generating capacity, with a maximum of 100%.
Results 1
Figure 1. PAS assay, LDH, fibrinogen and free hemoglobin values obtained for ten LVAD patients (1-10). PAS values are reported as mean +/- standard deviation
(number of replicates, n=10). Red arrows indicate patients who suffered clinically diagnosed thromboembolic events. * indicates statistically significant
difference (p<0.05). The Student–Newman–Keuls post hoc test was performed for comparisons between individual groups, after one-way ANOVA. The upper
physiological limit (black lines in the graphs) of LDH and fibrinogen concentrations are considered 220 U/L and 400 mg/dl, respectively. The lower physiological






















































































• Three patients had thromboembolic events following LVAD implantation
(Pt.1 – VAD thrombosis, Pt.5 and Pt.10 – brain stroke).
• The level of platelet activation detected for patients with thromboembolic
conditions (Pt.1 – 15,6 ± 1,9%; Pt.5 – 3 ± 1,1%; Pt.10 – 12 ± 2,3%) was
significantly higher compared to the other patients studied (mean value
0,54 ± 0,27%).
• LDH, fibrinogen and free hemoglobin concentrations detected in all
subjects were altered with respect to physiological values (except for
fibrinogen level in Pt.7, see Fig. 1).
• LDH, fibrinogen and free hemoglobin concentrations were not able to
discriminate between patients with thromboembolic events (Pt.1, 5 and
10) versus the other patients studied.
Conclusions
• Thromboembolic events are associated with higher level of platelet
activation.
• The PAS assay appeared to be a sensitive tool for detecting abnormal
levels of platelet activation in association with VAD-related
thromboembolic events.
• Other clinical diagnostic measurements (LDH, fibrinogen, free hemoglobin
concentration) may indicate the coagulation status of both patients and
VADs but resulted to be a less sensitive methodology to determine shear-
mediated platelet activation.
• Additional studies aimed at realizing a new-generation of diagnostic
devices utilizing the PAS assay technique may help limit post-implantation
complication rates and pharmacological therapy costs.
